5 Key Takeaways
-
1
Beacon Therapeutics presented interim data from the DAWN phase 2 trial of laru-zova for XLRP at the ARVO 2025 Annual Meeting.
-
2
Laru-zova aims to restore function in XLRP by delivering a functional RPGRORF15 gene using a specialized vector.
-
3
The DAWN trial showed that laru-zova was generally well-tolerated and improved visual function in participants.
-
4
The study evaluates two dose levels of laru-zova in patients previously treated with AAV vector-based gene therapy.
-
5
Beacon Therapeutics is enrolling patients for its pivotal phase 2/3 VISTA trial of laru-zova for XLRP.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.